Kissei Pharmaceutical Co. Ltd
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thr… Read more
Kissei Pharmaceutical Co. Ltd (KSPHF) - Total Liabilities
Latest total liabilities as of September 2025: $48.50 Billion USD
Based on the latest financial reports, Kissei Pharmaceutical Co. Ltd (KSPHF) has total liabilities worth $48.50 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kissei Pharmaceutical Co. Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how Kissei Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kissei Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Kissei Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
China | CN¥13.05 Billion |
|
Cofoe Medical Technology Co.Ltd.
SHE:301087
|
China | CN¥1.57 Billion |
|
Motorcomm Electronic Technology Co. Ltd. A
SHG:688515
|
China | CN¥143.74 Million |
|
JC Finance & Tax Interconnect Holdings Ltd
SHE:002530
|
China | CN¥760.85 Million |
|
Mahanagar Gas Limited
NSE:MGL
|
India | ₹24.41 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Kissei Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kissei Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kissei Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual total liabilities of Kissei Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $33.93 Billion | -14.73% |
| 2024-03-31 | $39.80 Billion | +19939.29% |
| 2023-03-31 | $198.58 Million | -33.24% |
| 2022-03-31 | $297.46 Million | -32.79% |
| 2021-03-31 | $442.57 Million | +23.07% |
| 2020-03-31 | $359.60 Million | +28.06% |
| 2019-03-31 | $280.81 Million | -14.54% |
| 2018-03-31 | $328.58 Million | +26.19% |
| 2017-03-31 | $260.39 Million | -16.90% |
| 2016-03-31 | $313.36 Million | -98.98% |
| 2015-03-31 | $30.77 Billion | +3.14% |
| 2014-03-31 | $29.83 Billion | +18.16% |
| 2013-03-31 | $25.25 Billion | +20.21% |
| 2012-03-31 | $21.00 Billion | -5.89% |
| 2011-03-31 | $22.32 Billion | -2.13% |
| 2010-03-31 | $22.80 Billion | +4.76% |
| 2009-03-31 | $21.77 Billion | -31.53% |
| 2008-03-31 | $31.79 Billion | -21.21% |
| 2007-03-31 | $40.35 Billion | -19.06% |
| 2006-03-31 | $49.85 Billion | +11.36% |
| 2005-03-31 | $44.77 Billion | -- |